The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee is set to review seven peptides, including BPC-157 and TB-500, to determine their eligibility for compounding. These peptides have gained popularity on social media for purported benefits like longevity and cognitive enhancement, but lack robust human clinical evidence for safety and efficacy. The FDA's own scientists have recommended against changing their status, and concerns exist regarding potential bias among committee members due to industry ties. AI
RANK_REASON Regulatory body reviewing substances with potential public health implications. [lever_c_demoted from significant: ic=1 ai=0.1]
- BPC-157
- Emideltide
- Epitalon
- Pharmacy Compounding Advisory Committee
- semaglutide
- Semax
- TB-500
- tirzepatide
- U.S. Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
